Sanofi Q2 2025 Financial Statements and Opella Divestiture

Sanofi has released its unaudited condensed half-year consolidated financial statements for the period ending June 30, 2025. The financials reflect the reclassification of Opella as a discontinued operation, with comparative figures for 2024 adjusted accordingly. Key highlights include the impact of the derecognition of non-controlling interests in Opella, the issuance of restricted shares to former Opella employees, and the accounting treatment of OPAL JV Co using the equity method following the loss of control of Opella. The financial statements also detail the company's commercial paper program, foreign exchange gains and losses, and contributions to pension funds. Additionally, the report mentions the acquisition of Dren-0201 and the net cash outflow from the acquisition of Inhibrx, Inc. The financials provide a comprehensive view of Sanofi's financial position, including its debt, equity, and cash flow activities for the first half of 2025.